Advertisement

Breast Cancer Research and Treatment

, Volume 3, Issue 4, pp 355–364 | Cite as

Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy

  • Bernard Fisher
  • Carol K. Redmond
  • D. Lawrence Wickerham
  • Howard E. Rockette
  • Ann Brown
  • Joseph Allegra
  • David Bowman
  • David Plotkin
  • Janet Wolter
  • other NSABP investigators
Report

Summary

In 1977 the National Surgical Adjuvant Breast and Bowel Project (NSABP) initiated a prospectively randomized clinical trial to evaluate the relative merits of 1-phenylalanine mustard and 5-fluorouracil (PF) with and without tamoxifen (T) as adjuvant therapy for patients with primary breast cancer and positive axillary nodes. A previous presentation of findings noted that there was a strong relationship between the outcome of those receiving PFT and the estrogen receptor (ER) and progesterone receptor (PR) content of their tumors. This report relates the outcome of the PF-treated patients in that trial with these tumor receptors. It indicates that the results observed following nonhormonal therapy (PF) are also related to tumor receptors.

Both the disease-free survival (DFS) and survival (S) of women following PF therapy were influenced by the ER and PR content of their tumors. Subsequent to adjustment for other prognostic variables, the predictive influence of tumor ER persisted. Both the DFS (p = 0.0003) and the S (p = 0.00003) were significantly higher in those with ≥ 10 fmol tumor ER than in those with < 10 fmol ER. The PR significantly added to the predictive value of ER. Thus, this analysis is the first to demonstrate that having information on both ER and PR is important for predicting outcome of patients receiving adjuvant chemotherapy. The study does not provide information which correlates receptor status with the response of patients to adjuvant chemotherapy since there is no similar nonchemotherapy-treated group of patients in the trial. The findings continue to emphasize that there is a heterogeneity in outcome of breast cancer patients to adjuvant chemotherapy which is related to an increasing number of host and tumor variables. For proper assessment of overall results, it is essential that analyses employ tests for interaction to indicate homogeneity or heterogeneity of patient subsets and that adjustments be made for imbalances in tumor ER and PR as well as in other prognostic factors.

Keywords

adjuvant chemotherapy breast cancer estrogen receptor progesterone receptor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McGuire WL, Horwitz KB, Pearson OH, Segaloff A: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39:2934–2947, 1977PubMedCrossRefGoogle Scholar
  2. 2.
    Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HMT, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223–1228, 1978PubMedCrossRefGoogle Scholar
  3. 3.
    Jonat W, Maass H: Some comments on the necessity of receptor determination in human breast cancer. Cancer Res 38:4305–4306, 1978PubMedGoogle Scholar
  4. 4.
    Kaufmann M, Klinga K, Runnebaum B, Kubli F: Hormone receptors in breast cancer and response to chemotherapy. (Letter to Editor). N Engl J Med 300:1052, 1979PubMedCrossRefGoogle Scholar
  5. 5.
    Frenning DH, Kennedy BJ, Vosika GJ, Kiang DT: Correlation of estrogen receptors and response to chemotherapy in advanced breast cancer. ASCO Abstracts, March 1978, p 347Google Scholar
  6. 6.
    Kiang DT, Frenning DH, Goldman AI, Ascensao VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330–1334, 1978PubMedCrossRefGoogle Scholar
  7. 7.
    Kiang DT, Frenning DH, Gay J, Goldman AI, Kennedy BJ: Estrogen receptor status and response to chemotherapy in advanced breast cancer. Cancer 46:2814–2817, 1980PubMedCrossRefGoogle Scholar
  8. 8.
    Young PCM, Ehrlich CE, Einhorn LH: Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer. Cancer 46:2961–2963, 1980PubMedCrossRefGoogle Scholar
  9. 9.
    Mortimer J, Reimer R, Greenstreet R, Groppe C, Bukowski R: Influence of estrogen receptor status on response to combination chemotherapy for recurrent breast cancer. Cancer Treat Rep 65:763–766, 1981PubMedGoogle Scholar
  10. 10.
    Chang JC, Wergowske G: Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer. Cancer 48:2503–2506, 1981PubMedCrossRefGoogle Scholar
  11. 11.
    Paone JF, Abeloff MD, Ettinger DS, Arnold EA, Baker RR: The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. Surg Gynecol Obstet 152:70–74, 1981PubMedGoogle Scholar
  12. 12.
    Hilf R, Feldstein ML, Savlov ED, Gibson SL, Seneca B: The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46:2797–2800, 1980PubMedCrossRefGoogle Scholar
  13. 13.
    Rubens RD, King RJB, Sexton S, Minton MJ, Hayward JL: Oestrogen receptors and response to cytotoxic chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 4:43–45, 1980PubMedCrossRefGoogle Scholar
  14. 14.
    Hilf R, Feldstein ML, Gibson SL, Savlov ED: The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45:1993–2000, 1980PubMedCrossRefGoogle Scholar
  15. 15.
    Rosenbaum C, Marsland TA, Stolbach LL, Raam S, Cohen JL: Estrogen receptor status and response to chemotherapy in advanced breast cancer: The Tufts-Shattuck-Pondville Experience. Cancer 46:2919–2921, 1980PubMedCrossRefGoogle Scholar
  16. 16.
    Bonadonna G, Valagussa P, Tancini G, Di Fronzo G: Estrogen receptors status and response to chemotherapy in early and advanced breast cancer. Cancer Chemother Pharmacol 4:37–41, 1980PubMedCrossRefGoogle Scholar
  17. 17.
    Gapinski PV, Donegan WL: Estrogen receptors and breast cancer: Prognostic and therapeutic implications. Surgery 88:386–393, 1980PubMedGoogle Scholar
  18. 18.
    Rosner D, Nemoto T: A randomized study of two and three drug regimen in relation with estrogen receptors in metastatic breast cancer. ASCO Abstracts, 1979, p 46Google Scholar
  19. 19.
    Carter SK: The dilemma of estrogen receptors and the response rate to cytotoxic chemotherapy: A problem of comparability analysis. Cancer Clin Trials 2:49–53, 1979PubMedGoogle Scholar
  20. 20.
    Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Marchini S, Veronesi U: Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: The Milan Institute experience. Rec Results Cancer Res 80:149–156, 1982Google Scholar
  21. 21.
    Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H, and Other NSABP Investigators: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305:1–6, 1981PubMedCrossRefGoogle Scholar
  22. 22.
    Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J, and Fisher ER, with the contributions of Plotkin D, Bowman D, Wolter J, Bornstein R, Desser R, Frelick R, and Other NSABP Investigators: Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J. Clin Oncol 1:227–241, 1983PubMedGoogle Scholar
  23. 23.
    Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER, and Other Cooperative Investigators: 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: A report of early findings. N Engl J Med 292:117–122, 1975PubMedCrossRefGoogle Scholar
  24. 24.
    Byar DP, Green SB: The choice of treatment for cancer patients based on covariate information: Application to prostate cancer. Bull Cancer 67:477–490, 1980PubMedGoogle Scholar
  25. 25.
    Elandt-Johnson RC, Johnson NL: Survival Models and Data Analysis, John Wiley & Sons, New York, 1980Google Scholar
  26. 26.
    Cox DR: Regression models and life-tables. J Roy Stat Soc (B) 34:187–220, 1972Google Scholar
  27. 27.
    Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170, 1966PubMedGoogle Scholar
  28. 28.
    Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J Roy Stat Soc (A) 135:185–206, 1972CrossRefGoogle Scholar
  29. 29.
    Cooke T, George D, Shields R, Maynard P, Griffiths K: Oestrogen receptors and prognosis in early breast cancer. Lancet 1:995–997, 1979PubMedCrossRefGoogle Scholar
  30. 30.
    Knight WA, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669–4671, 1977PubMedGoogle Scholar
  31. 31.
    Sarrif AM, Durant JR: Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor. Cancer 48:1215–1220, 1981PubMedCrossRefGoogle Scholar
  32. 32.
    Fisher B, Wickerham DL, Brown A, and Redmond CK, with the contributions of Cunningham TJ, Evans J, Legault-Poisson S, Paterson AHG, Schipper H, and Other NSABP Investigators: Breast cancer estrogen and progesterone receptor values: Their distribution, degree of concordance and relation to number of positive axillary nodes. J Clin Oncol 1:349–358, 1983PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • Bernard Fisher
    • 1
  • Carol K. Redmond
    • 2
  • D. Lawrence Wickerham
    • 1
  • Howard E. Rockette
    • 2
  • Ann Brown
    • 3
  • Joseph Allegra
    • 4
  • David Bowman
    • 5
  • David Plotkin
    • 6
  • Janet Wolter
    • 7
  • other NSABP investigators
    • 8
  1. 1.Department of Surgery, School of MedicineUniversity of PittsburghPittsburghUSA
  2. 2.Department of BiostatisticsUniversity of PittsburghPittsburghUSA
  3. 3.NSABP Biostatistical CenterUniversity of PittsburghPittsburghUSA
  4. 4.Department of Medical OncologyJames Graham Brown Cancer CenterLouisvilleUSA
  5. 5.Manitoba Cancer Treatment and Research FoundationHealth Sciences CenterWinnipegCanada
  6. 6.Memorial Cancer Research Foundation of Southern CaliforniaCulver CityUSA
  7. 7.Department of Medical OncologyRush Presbyterian-St. Luke's HospitalChicagoUSA
  8. 8.National Surgical Adjuvant Breast and Bowel Project (NSABP) HeadquartersPittsburghUSA

Personalised recommendations